Since current data suggests that AMD3100 may not be safe or effective as an anti-CXCR4 antagonist for therapeutic applications in pancreatic cancer, specific antagonists remain to be identified for this purpose. This evidence concerns the gene CXCR4 and pancreatic neoplasm.